L. Hung

发表

Oral Treatment with CuII(atsm) Increases Mutant SOD1 In Vivo but Protects Motor Neurons and Improves the Phenotype of a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis

Blaine R. Roberts, James L. Hickey, C. Masters, 2014, The Journal of Neuroscience.

Oral Treatment with Cu [ superscript II ] ( atsm ) Increases Mutant SOD 1 In Vivo but Protects Motor Neurons and Improves the Phenotype of a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis

James L. Hickey, C. Masters, A. Bush, 2014 .

Diacetylbis(N(4)-methylthiosemicarbazonato) Copper(II) (CuII(atsm)) Protects against Peroxynitrite-induced Nitrosative Damage and Prolongs Survival in Amyotrophic Lateral Sclerosis Mouse Model*

James L. Hickey, C. Masters, P. Crouch, 2011, The Journal of Biological Chemistry.

Analysis of Abeta interactions using ProteinChip technology.

J. Wade, E. Giannakis, K. Barnham, 2008, Methods in molecular biology.

Targeting metals rescues the phenotype in an animal model of tauopathy.

A. Bush, R. Cherny, P. Adlard, 2018, Metallomics : integrated biometal science.

Restoration of intestinal function in an MPTP model of Parkinson’s Disease

J. Culvenor, J. Furness, D. Finkelstein, 2016, Scientific Reports.

Elucidating the role of metals in Alzheimer's disease through the use of Surface-Enhanced Laser Desorption/Ionisation time-of-flight mass spectrometry.

Keyla A. Perez, L. Hung, A. Watt, 2011, Methods in molecular biology.

The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson’s disease

Blaine R. Roberts, David M. Shackleford, C. Masters, 2012, The Journal of experimental medicine.

Modulating Protein Phosphatase 2A Rescues Disease Phenotype in Neurodegenerative Tauopathies.

Lesley Cheng, A. Hill, P. Adlard, 2018, ACS chemical neuroscience.

The Alzheimer’s therapeutic PBT2 promotes amyloid‐β degradation and GSK3 phosphorylation via a metal chaperone activity

C. Masters, A. Bush, R. Cherny, 2011, Journal of neurochemistry.

Rabies screen reveals GPe control of cocaine-triggered plasticity

Karl Deisseroth, Liqun Luo, Robert C. Malenka, 2017, Nature.

Ablation of tau causes an olfactory deficit in a murine model of Parkinson’s disease

A. Hill, A. Bush, M. Lazarou, 2018, Acta Neuropathologica Communications.

Increasing Cu bioavailability inhibits Aβ oligomers and tau phosphorylation

C. Masters, A. Bush, R. Cherny, 2009, Proceedings of the National Academy of Sciences.

Increasing Cu bioavailability inhibits A beta oligomers and tau phosphorylation

C. Masters, A. Bush, R. Cherny, 2009 .

Amyloid-β Peptide (Aβ) Neurotoxicity Is Modulated by the Rate of Peptide Aggregation: Aβ Dimers and Trimers Correlate with Neurotoxicity

C. Masters, R. Cappai, G. Ciccotosto, 2008, The Journal of Neuroscience.

P1-422: Abeta neurotoxicity is modulated by the rate of peptide aggregation: Abeta dimers and trimers correlate with neurotoxicity

C. Masters, R. Cappai, G. Ciccotosto, 2008, Alzheimer's & Dementia.

5-HT release in nucleus accumbens rescues social deficits in mouse autism model

K. Deisseroth, R. Malenka, A. Selimbeyoglu, 2018, Nature.

Oligomers, fact or artefact? SDS-PAGE induces dimerization of β-amyloid in human brain samples

C. Masters, V. Villemagne, A. Rembach, 2013, Acta Neuropathologica.

Gating of social reward by oxytocin in the ventral tegmental area

Kevin T. Beier, L. Luo, K. Deisseroth, 2017, Science.

Dimeric structures of alpha-synuclein bind preferentially to lipid membranes.

C. Masters, R. Cappai, J. Wade, 2008, Biochimica et biophysica acta.

Localized changes to glycogen synthase kinase-3 and collapsin response mediator protein-2 in the Huntington's disease affected brain.

A. Hannan, P. Crouch, Qiao-Xin Li, 2014, Human molecular genetics.

Rhenium and technetium complexes that bind to amyloid-β plaques.

P. Adlard, H. Tochon-Danguy, V. Villemagne, 2015, Dalton transactions.

Modulating metals as a therapeutic strategy for Alzheimer's disease.

K. Barnham, L. Hung, 2012, Future medicinal chemistry.

Development of a platinum complex as an anti-amyloid agent for the therapy of Alzheimer's disease.

C. Masters, P. Adlard, R. Cappai, 2013, Angewandte Chemie.

High order W02-reactive stable oligomers of amyloid-β are produced in vivo and in vitro via dialysis and filtration of synthetic amyloid-β monomer.

C. Masters, A. Bush, R. Cherny, 2015, Journal of Alzheimer's disease : JAD.